Related Experiment Video
Updated: Apr 1, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
22.2K
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide
Supriya Mallick1, Ajeet Kumar Gandhi2, Daya Nand Sharma1
1Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
Summary
This study suggests that adjuvant radiotherapy and temozolomide are well-tolerated and improve survival for pediatric gliosarcoma (pPGS). These findings offer hope for this rare and aggressive pediatric brain tumor.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Rare Cancers
Background:
- Primary pediatric gliosarcoma (pPGS) is an exceptionally rare brain tumor with limited reported cases.
- The efficacy of temozolomide in conjunction with radiotherapy for pPGS remains largely unknown.
Purpose of the Study:
- To evaluate the safety and survival outcomes of concurrent and adjuvant temozolomide combined with radiotherapy in pediatric gliosarcoma patients.
- To analyze pooled survival data from existing literature and a new cohort of pPGS patients.
Main Methods:
- Retrospective analysis of five pPGS patients treated between 2006 and 2011.
- Maximal safe surgical resection followed by adjuvant radiotherapy (60 Gy) with concurrent and maintenance temozolomide.
- Kaplan-Meier analysis of progression-free survival (PFS) and overall survival (OS) using pooled data from 30 patients.
Main Results:
- The study included five patients with a median age of 12 years; the male to female ratio was 1:4.
- Four patients completed the full adjuvant treatment protocol; median follow-up was 22.6 months.
- Pooled data from 30 patients showed a median PFS of 12 months and median OS of 43 months, with 2-year PFS and OS rates of 44.2% and 62.9%, respectively.
Conclusions:
- Adjuvant radiotherapy and temozolomide demonstrate encouraging survival rates in pediatric gliosarcoma.
- The treatment regimen was well-tolerated in the studied patient cohort.
- This approach offers a promising therapeutic strategy for managing this rare pediatric brain tumor.
